Defining the host antiviral response to West Nile Virus

定义宿主对西尼罗河病毒的抗病毒反应

基本信息

  • 批准号:
    7980162
  • 负责人:
  • 金额:
    $ 5.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): West Nile Virus (WNV) is an NIAID Category B infectious agent and since its introduction into the United States in 1999, has become the leading cause of arboviral encephalitis in the United States. In recent WNV outbreaks, healthy young adults have been afflicted with increasing incidences of neurological disease demonstrating that virulence can occur independently of senescence or immune deficiencies associated with aging. This suggests that pathogenic strains of WNV in the United States modulate immunity sufficiently to cause disease in healthy young adults. At this point, there is no vaccine against WNV and treatment is only supportive. The WNV interactions with the innate immune signaling pathways are not well defined. Studies from our laboratory have demonstrated that type I interferon (IFN) is critical in controlling WNV replication and virulence. Our laboratory has also found that innate immune signaling from the host cytoplasmic viral sensors, RIG-I and MDA5, are critical in triggering an innate immune response to WNV. However, their in vivo relevance or their roles in triggering cell and tissue- specific antiviral defense programs against WNV are well not defined. To address these issues, the following objectives have been outlined in this proposal: 1) Define the roles of RIG-I and MDA-5 in triggering the host innate immune response against lineage I and lineage II West Nile virus strains; 2) Define the innate immune effector genes that regulate WNV infection. We will utilize cell-based, biochemical, virological, and a functional genomics approach to define the roles of, RIG-I, and MDA5, and the IPS-1 adaptor protein. We will utilize knockout mice and primary cells generated from these mice to evaluate virulence, viral spread, cell tropism, and pathogenesis to define the innate immune response triggered by West Nile virus infection. These studies will more clearly define the interface between the host immune response and WNV pathogenesis and provide novel insights to guide therapeutic and vaccine strategies aimed at modulating immunity to infection. PUBLIC HEALTH RELEVANCE: Since 1999, WNV has emerged as a significant public health threat. In 2007, WNV caused 3598 cases of infection with symptoms ranging from meningitis, encephalitis, and debilitating fever and caused 121 fatalities. With no vaccine available and therapy to infection being only minimal, studies have to be conducted to better define the interface between the host antiviral response and WNV pathogenesis.
描述(由申请人提供):西尼罗河病毒(WNV)是NIAID B类传染性病原体,自1999年引入美国以来,已成为美国虫媒病毒性脑炎的主要原因。在最近的西尼罗河病毒爆发中,健康的年轻人受到神经系统疾病发病率增加的折磨,这表明毒力可以独立于衰老或与衰老相关的免疫缺陷而发生。这表明,在美国的致病株西尼罗河病毒调节免疫力足以导致健康的年轻人的疾病。在这一点上,没有针对西尼罗河病毒的疫苗,治疗只是支持性的。西尼罗河病毒与先天免疫信号通路的相互作用还没有很好的定义。我们实验室的研究表明,I型干扰素(IFN)在控制西尼罗河病毒复制和毒力方面至关重要。我们的实验室还发现,来自宿主细胞质病毒传感器RIG-I和MDA 5的先天免疫信号传导在触发对WNV的先天免疫应答中至关重要。然而,它们的体内相关性或它们在触发针对西尼罗河病毒的细胞和组织特异性抗病毒防御程序中的作用还没有很好地确定。为了解决这些问题,本提案中概述了以下目标:1)确定RIG-I和MDA-5在触发针对谱系I和谱系II西尼罗河病毒株的宿主先天免疫应答中的作用; 2)确定调节西尼罗河病毒感染的先天免疫效应基因。我们将利用基于细胞的,生物化学,病毒学和功能基因组学的方法来定义,RIG-I,和MDA 5,和IPS-1衔接蛋白的作用。我们将利用基因敲除小鼠和从这些小鼠产生的原代细胞来评估毒力、病毒传播、细胞嗜性和发病机制,以确定西尼罗河病毒感染引发的先天免疫反应。这些研究将更清楚地定义宿主免疫反应和西尼罗河病毒发病机制之间的界面,并提供新的见解,以指导旨在调节免疫感染的治疗和疫苗策略。公共卫生相关性:自1999年以来,西尼罗河病毒已成为一个重大的公共卫生威胁。2007年,西尼罗河病毒造成3598例感染病例,症状包括脑膜炎、脑炎和衰弱性发热,并造成121人死亡。由于没有可用的疫苗和治疗感染只有最低限度,研究必须进行,以更好地确定宿主抗病毒反应和西尼罗河病毒发病机制之间的接口。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mehul Shamal Suthar其他文献

Mehul Shamal Suthar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mehul Shamal Suthar', 18)}}的其他基金

Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
  • 批准号:
    10402864
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Cell-intrinsic role of caspase-1 in regulating antigen-specific CD8+ T cell responses
Caspase-1 在调节抗原特异性 CD8 T 细胞反应中的细胞内在作用
  • 批准号:
    10171780
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
  • 批准号:
    10058046
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
  • 批准号:
    10624960
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
了解胎盘内抗体介导的 ZIKV 转胞吞作用机制
  • 批准号:
    10189512
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Identifying host genetic determinants that regulate dendritic cell activation
识别调节树突状细胞激活的宿主遗传决定因素
  • 批准号:
    8893467
  • 财政年份:
    2015
  • 资助金额:
    $ 5.22万
  • 项目类别:
Identifying host genetic determinants that regulate dendritic cell activation
识别调节树突状细胞激活的宿主遗传决定因素
  • 批准号:
    9094679
  • 财政年份:
    2015
  • 资助金额:
    $ 5.22万
  • 项目类别:
Regulation of T cell immunity by the cytosolic RIG-I like receptors
胞质 RIG-I 样受体对 T 细胞免疫的调节
  • 批准号:
    8897470
  • 财政年份:
    2014
  • 资助金额:
    $ 5.22万
  • 项目类别:
Generation of MAVS conditional KO mice to study cell-type specific immunity
生成 MAVS 条件 KO 小鼠以研究细胞类型特异性免疫
  • 批准号:
    8787074
  • 财政年份:
    2013
  • 资助金额:
    $ 5.22万
  • 项目类别:
Generation of MAVS conditional KO mice to study cell-type specific immunity
生成 MAVS 条件 KO 小鼠以研究细胞类型特异性免疫
  • 批准号:
    8623700
  • 财政年份:
    2013
  • 资助金额:
    $ 5.22万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了